Minimal Residual Disease–Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing-Reference-Cited by-同舟云学术

Minimal Residual Disease–Guided Intermittent Dosing in Patients With Cancer: Successful Treatment of Chemoresistant Anaplastic Large Cell Lymphoma Using Intermittent Lorlatinib Dosing

Published:2022-06 Issue:6 Volume: Page:
ISSN:2473-4284
Container-title:JCO Precision Oncology
language:en
Short-container-title:JCO Precision Oncology

Author:

Pokorna Petra¹^ORCID,Lakka Klement Giannoula²³^ORCID,Vasikova Alzbeta⁴,Kanderova Veronika⁵,Jezova Marta⁶,Noskova Kristyna⁷⁸^ORCID,Mudry Peter²,Kyr Michal²^ORCID,Merta Tomas²,Bajciova Viera²^ORCID,Krenova Zdenka²,Palova Hana¹,Valik Dalibor⁹^ORCID,Zdrazilova Dubska Lenka¹⁰^ORCID,Slaby Ondrej¹¹¹,Sterba Jaroslav²¹²^ORCID

Affiliation:

1. Central European Institute of Technology, Masaryk University, Brno, Czech Republic

2. Department of Pediatric Oncology, University Hospital Brno, and Faculty of Medicine, Masaryk University, Brno, Czech Republic

3. CSTS Health Care, Toronto, ON, Canada

4. Department of Internal Medicine-Hematology and Oncology, University Hospital Brno, and Faculty of Medicine, Masaryk University, Brno, Czech Republic

5. CLIP, Department of Pediatric Hematology/Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic

6. Department of Pathology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic

7. Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic

8. Clinical Pharmacy Section of Hospital Pharmacy, University Hospital Brno, Brno, Czech Republic

9. Department of Laboratory Methods, Faculty of Medicine, Masaryk University, Brno, Czech Republic

10. Department of Clinical Microbiology and Immunology, University Hospital Brno, and Faculty of Medicine, Masaryk University, Brno, Czech Republic

11. Department of Biology, Faculty of Medicine, Masaryk University, Brno, Czech Republic

12. International Clinical Research Center, St Anne's University Hospital, Brno, Czech Republic

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/PO.21.00525

Reference25 articles.

1. Anaplastic large cell lymphoma in paediatric and young adult patients

2. Relapses of childhood anaplastic large-cell lymphoma: Treatment results in a series of 41 children - a report from the French Society of Pediatric Oncology

3. Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

4. Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children’s Oncology Group Study

5. Abrupt Relapse of ALK-Positive Lymphoma after Discontinuation of Crizotinib

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overcoming Brigatinib Resistance with Lorlatinib in Pediatric ALK Positive Anaplastic Large Cell Lymphoma with Acquired ALK p.F1174V Mutation – a Case Report;Precision Oncogenomics;2024-08-12

2. Liquid biopsy in T-cell lymphoma: biomarker detection techniques and clinical application;Molecular Cancer;2024-02-17

3. Biopathology of childhood, adolescent and young adult non-Hodgkin lymphoma;Best Practice & Research Clinical Haematology;2023-03